期刊文献+

龙岩市2012年疑似预防接种异常反应监测分析 被引量:1

Surveillance of suspect adverse events following immunization in Longyan city in 2012
下载PDF
导出
摘要 目的分析预防接种疑似异常反应(AEFI)的发生特征,评价AEFI信息管理系统运行状况和疫苗免疫的安全性。方法用描述性流行病学方法分析2012年度龙岩市疑似预防接种异常反应信息管理系统的数据。结果2012年龙岩市共报告AEFI 215例,其中一般反应182例(84.65%),异常反应30例(13.95%),偶合症2例(0.93%),心因性反应1例(0.47%)。23价肺炎疫苗引起AEFI的发生率最高,达74.55/10万剂次。0岁~2岁组儿童发生AEFI最多,占73.08%。 AEFI报告完整率达100%,48 h内及时报告率为77%,48 h内及时调查率为98%,3 d内调查表报告率为70%。结论 AEFI报告质量和疫苗安全性良好,全市AEFI监测的完整性较好,但报告和调查的及时性有待提高。 Objective To analyze the features of the suspect adverse events following immunization (AEFI) in Longyan , and to evaluate the report quality of the Information Management System and the safety of vaccines. Methods Descriptive epidemiological methods were used to analyze theAEFI cases reported by AEFI information management system in 2012. Results A total of 215 AEFI cases were reported in longyan in 2012,including 182(84.65%)genneral reaction cases,30 (13.95%)adverse reaction cases,2 (0.93%)coincident cases,1 (0.47%)cases due to psychoenic reation. THE highest rate of AEFI was caused by 23-valent pneumococcal caccine,which reported AEFI rate was 74.55per 10 million doses. The most AEFI cases were happened in 0-2 years old group,accounted for 73.08%.The reported integrity rate reached 100%,the timely report rate in 48 hours was 77%,the prorotion of investigated cases within 48h was 98%,the timely investigation rate in 48 hours was 70%.Conclusion The study showed that the quality of AEFI reported and the safety of vaccines were satisfactory. The integrality and timeliness rates of surveillance system were good,but that deed to be improved as well.
出处 《基层医学论坛》 2013年第28期3690-3692,共3页 The Medical Forum
关键词 预防接种 安全性 疑似预防接种异常反应 监测 Vaccinate Safty Suspect adverse events Surveillance
  • 相关文献

参考文献6

二级参考文献25

  • 1刘大卫.如何开展预防接种异常反应监测工作[J].中国计划免疫,2006,12(4):322-327. 被引量:65
  • 2卫生部.全国疑似预防接种异常反应监测方案[S].2010-06-03.
  • 3卫生部.预防接种副反应监测试点工作指南[S].2005.
  • 4谢广中.重视预防接种的异常反应[J].上海预防医学,2007,19(10):515-517. 被引量:9
  • 5Deepika M, Jane C, Peter B, et al. Annual Report: Surveillance of Adverse Events Following Immunization in Australia, 2010[J]. CDI,2011,35 (4) :263-280.
  • 6WHO&WPRO. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization [ S]. Manila, Philippines, 1999.
  • 7Pless RP, Bentsi-Enchill AD, Duclos P, et al. Monitoring Vaccine Safety during Measles Mass Immunization Campaigns: Clinical and Programmatic Issues [J ]. The Journal of Infectious Diseases, 2003,187 (Suppll) :S291-298.
  • 8Haber P, Sejvar J, Mikaeloft Y, et al. Vaccines and GuiUain-Barre Syndrome [ J ]. Drug Safety, 2009, 32 (4) :309-323.
  • 9Dipacla JA, Buchanan GR. Immune Thrombocy topenic Purpura [J ]. Pediatr Clin North America, 2002,49 (5) :911-928.
  • 10Jens UR, Michael SG, Jose-Maria B, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data[J]. Vaccine, 2007,25 (31 ) :5675-5684.

共引文献250

同被引文献1

  • 1国家卫生部,国家食品药品监督管理局.全国疑似预防接种异常反应监测方案[S].卫办疾控发[2010]94号.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部